Unlock instant, AI-driven research and patent intelligence for your innovation.

Regulator genes of angiogenesis, pharmaceutical preparations containing them and their applications

a technology of angiogenesis and regulator genes, which is applied in the field of angiogenic disorders, can solve the problems of many pathologies linked to invasiveness, uncontrolled angiogenesis, and metastases in remote sites

Inactive Publication Date: 2011-05-05
GENE SIGNAL INT SA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These compositions and methods enable precise modulation of angiogenesis, allowing for the inhibition or promotion of neovessel formation, thereby providing potential therapeutic benefits for angiogenic disorders by targeting specific genes involved in the angiogenic process.

Problems solved by technology

However, many pathologies are linked to invasive, uncontrolled angiogenesis.
Furthermore, these neovessels present escape routes by means of which the tumors can reach the blood circulatory system and cause metastases in remote sites such as the liver, lungs or bones.
However, no role for the homeobox protein NKX3.1 has been reported to date in the regulation of angiogenesis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Regulator genes of angiogenesis, pharmaceutical preparations containing them and their applications
  • Regulator genes of angiogenesis, pharmaceutical preparations containing them and their applications

Examples

Experimental program
Comparison scheme
Effect test

examples

Material and Methods

1. Culture of the Cells and Angiogenesis Test

[0130]Human endothelial cells from umbilical veins (HUVEC) grown under the following four culture conditions (see WO 01 / 218312, supra) were used for identifying the genes coding for the cellular constituents implicated in the regulation of angiogenesis:

[0131]A control condition in which the endothelial cells are not stimulated.

[0132]An angiogenic condition in which the endothelial cells are stimulated by one or more angiogenic factors.

[0133]An angiogenesis inhibition condition in which the endothelial cells are stimulated by one or more angiogenic factors and brought into the presence of one or more angiostatic conditions.

[0134]Another control condition in which the endothelial cells are stimulated by one or more angiostatic factors.

[0135]The endothelial cells were maintained in complete medium (EGM-2-MV from Clonetics).

[0136]For the identification of the genes implicated in angiogenesis in the in vitro angiogenesis te...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

Nucleotide sequences and the corresponding polypeptide sequences implicated in the regulation of angiogenesis are identified. The nucleotide and polypeptide sequences, or pharmaceutical composition made from such sequences can be used in the clinical study of the angiogenesis process, the prognosis, diagnosis and treatment of pathologies linked to angiogenesis, and in the implementation of pharmaceutical, pharmacogenomic and drug identification trials.

Description

[0001]This application is a new divisional application of co-pending U.S. application Ser. No. 10 / 947,476 filed on Sep. 9, 2004, which is the 35 U.S.C. §371 national stage of International PCT / FR03 / 00912 filed on Mar. 21, 2003, which claimed priority to French Application No. FR 02 / 03655 filed on Mar. 22, 2002. The entire contents of each of the above-identified applications are hereby incorporated by reference.FIELD OF THE INVENTION[0002]The present invention pertains to the treatment of angiogenic disorders, in particular to pharmaceutical compositions that are useful for the treatment of pathologies resulting from a deregulation of the angiogenesis mechanism.BACKGROUND OF THE INVENTION[0003]Angiogenesis is a fundamental process by means of which new blood vessels are formed. This process is essential in many normal physiological phenomena such as reproduction, development and cicatrization. Angiogenesis is under strict control in these normal biological phenomena; i.e., it is tri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K31/7088A61K38/02A61K38/17C07H21/00C12N15/85C12Q1/68A61P19/02A61P27/02A61P29/00A61P9/10A61P15/00A61P17/06A61P9/00A61P35/00A61P19/10C07K14/47
CPCC07K14/47A61P15/00A61P17/06A61P19/02A61P19/10A61P27/02A61P29/00A61P35/00A61P9/00A61P9/10
Inventor AL-MAHMOOD, SALMANCOLIN, SYLVIESCHNEIDER, CHRISTOPHE
Owner GENE SIGNAL INT SA